l e t t e r s
Extensive changes in DNA methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor-suppressor genes 1 . Genome-scale studies have yielded important insights into these changes 2-5 but have focused on CpG islands or gene promoters. We used wholegenome bisulfite sequencing (bisulfite-seq) to comprehensively profile a primary human colorectal tumor and adjacent normal colon tissue at single-basepair resolution. Regions of focal hypermethylation in the tumor were located primarily at CpG islands and were concentrated within regions of long-range (>100 kb) hypomethylation. These hypomethylated domains covered nearly half of the genome and coincided with late replication and attachment to the nuclear lamina in human cell lines. We confirmed the confluence of hypermethylation and hypomethylation within these domains in 25 diverse colorectal tumors and matched adjacent tissue. We propose that widespread DNA methylation changes in cancer are linked to silencing programs orchestrated by the three-dimensional organization of chromatin within the nucleus.
We performed comprehensive methylome analysis of a CpG island (CGI) methylator phenotype (CIMP)-high 6 , stage 3 primary colon adenocarcinoma harboring a KRAS mutation resulting in p.Gly12Asp. We estimated the tumor DNA content of the sample at 67% using microarray-based SNP genotyping (Supplementary Figs. 1,2) . We used bisulfite-seq 7 to generate sequences of 76 billion uniquely alignable bp (28× average genome coverage) for the tumor sample and sequences of 87 billion bp (32× coverage) for a normal adjacent colon mucosa sample from the same individual (Supplementary Note). Approximately 80% of all genomic CpG dinucleotides were covered with five or more uniquely mapped sequencing reads in both samples (Supplementary  Tables 1,2) . Bisulfite-seq methylation levels showed strong concordance (Pearson correlations (r) of 0.93-0.97) with Illumina Infinium HumanMethylation27k methylation measurements. Regions of copy number alterations (114 Mb with gains and 223 Mb with losses) also yielded similar DNA methylation results for bisulfite-seq and the Infinium array (Supplementary Fig. 3 ). DNA methylation at nonCpG (CpH) cytosine contexts was almost undetectable, as has been reported for somatic cell lines and which is in contrast to human embryonic stem cells (hESCs) and induced pluripotent stem cells 8 ( Supplementary Fig. 4) . A representative 10-kb region of the genome shows dramatic differences between the tumor and normal colon tissue; DNA methylation in the tumor is higher within the CGI promoter region but is lower outside of the CGI (Fig. 1) .
We investigated global DNA methylation changes by comparing the methylation of tumor to adjacent normal mucosa in genome-wide windows as small as two adjacent CpG dinucleotides and as large as 20 kb (Supplementary Fig. 5 ). At all window sizes, the vast majority of windows were methylated in both tissues, but two clear clusters of normally unmethylated windows were present at window sizes less than 5 kb (Fig. 2a) . Based on these clusters, we identified discrete elements by screening for methylation within windows of five adjacent CpGs, defining those with an average methylation level <5% as unmethylated and those with a level >35% as methylated. This allowed the identification of 5,163 elements that were unmethylated in normal colon cells and methylated in the tumor (methylation prone) and 21,134 elements that were unmethylated in both (methylation resistant). Although less abundant, we identified 662 elements methylated in normal colon tissue and unmethylated in the tumor (methylation loss).
We compared these three methylation classes to genomic annotations and ENCODE 9 protein-DNA interactions (chromatin immunoprecipitation sequencing (ChIP-seq)) by examining genomic enrichment relative to randomly selected regions in the genome (Fig. 2b and Supplementary Fig. 6 ). Although only 29% of methylationprone elements corresponded to known promoters (transcription start sites (TSS)), they almost universally (95%) coincided with CGIs 10 and were highly enriched for marks of polycomb repressive complex 1 and 2 activity in hESCs. Although earlier work has shown enrichment of polycomb sites at methylation-prone promoters 6,11-13 , Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains non-promoter regulatory regions have not been well characterized. We found that non-promoter regions containing the known enhancer marks p300 (ref. 14) and H3K27ac 15 were more likely to be methylation resistant than promoters, but those non-promoter regions that were methylation prone were, like promoters, primarily at CGIs and were highly overlapping with polycomb marks. Binding of the transcription factors Sp1, Nrf1 or YY1 can protect CGIs from cancerspecific DNA methylation 4, 16 , and we found this protective property to extend to most of the 55 transcription factors present in ENCODE; methylation-resistant elements were strongly enriched for almost all factors (median enrichment 22×), whereas methylation-prone elements were only weakly enriched (median enrichment 4×). Similarly, methylation-resistant elements had 29× enrichment for CTCF insulator binding sites 17 (51% of methylation-resistant elements overlapped a CTCF site), whereas methylation-prone elements only had 7× enrichment for these sites (13% of all methylation-prone elements overlapped a CTCF site). Consistent with an earlier report 18 , methylation-prone elements were strongly depleted of Alu repeats and other short and long interspersed elements relative to methylationresistant and methylation-loss elements (Fig. 2b) .
We performed microarray expression analysis and found that methylation-prone promoters, both CGI and non-CGI, were associated with low expression in normal colon tissue and with loss of expression in the tumor (Supplementary Fig. 8 ). Genes silenced in the tumor gained methylation across an entire CGI promoter (MGMT) (Fig. 3a) or within an isolated portion of a promoter (MAF). We used the program HOMER 19 to identify sequence motifs enriched within either methylation-resistant or methylation-prone elements ( Fig. 3b and Supplementary Figs. 13-15) . In agreement with a recent study 4 , methylation-prone elements were enriched for CA and GA dinucleotide repeats, and methylation-resistant elements were enriched for numerous sequences matching known transcription factor binding motifs, including Nrf1, Sp1, GABPA, YY1 and NF-Y ( Fig. 3b and  Supplementary Fig. 14) .
Compared to methylation-prone and methylation-resistant elements, those elements losing methylation in the tumor (methylation loss) occurred less frequently at promoters (3%) and CGIs (26%) but were generally enriched in ENCODE transcription factor binding sites including TAF1 ( Fig. 2b ; median enrichment 11.4×), suggesting that many of these elements act as either unannotated promoters or transcriptional enhancers. Methylation-loss elements, whether at a promoter or an enhancer, were more likely to be associated with genes that gained expression in the tumor (Supplementary Fig. 7 ), which is in contrast to methylation-prone elements. B3GNTL1 and TACSTD2 are both upregulated in the tumor and contain methylation-loss elements within putative enhancers with sites for the Fos and Jun transcription factors (Fig. 3a) . The predominantly over-represented sequence motif within methylation-loss elements corresponded to the AP-1 binding sequence of the Fos-Jun dimer (Fig. 3b) , making it tempting to speculate that methylation loss l e t t e r s l e t t e r s reflects chromatin remodeling initiated by Fos-Jun at these sites, a process known to play a crucial role in intestinal proliferation and oncogenesis 20 . Genome-wide methylation changes at varying window sizes showed that the majority of the genome that was methylated could be resolved into two distinct fractions in windows of 20 kb (Fig. 4a) . One fraction was markedly hypomethylated in the tumor, resembling the partially methylated domains (PMDs) that occur in somatic cell lines but not hESCs 8 . Based on this profile, we identified PMDs genome wide by searching for 10-kb windows with an average methylation of 20-60% and then collapsing these into domains longer than 100 kb; in all, 44% of the tumor genome was contained within these PMD domains (Fig. 4b) . We found diverse somatic cell lines to share close to 75% of the PMDs 8 , and we found that about 75% of IMR-90 fibroblast PMDs were contained within colon tumor PMDs. Although tumor Figs. 13-15) . Because methylation-prone and methylation-resistant elements most often corresponded to CGI TSS, alignments for these two classes are relative to the oriented TSS, whereas those for the methylation-loss class (right) show alignments relative to the center of the unoriented methylation-loss element. Matches to known motifs from the HOMER database are shown below the de novo motif they match (Nrf1 and AP-1). l e t t e r s PMD regions had slightly reduced methylation in normal colon cells (Fig. 4a) , virtually none of them satisfied our PMD criteria (Fig. 4b) , indicating a shared property of immortalized cell lines and tumors that is absent from normal somatic tissues.
To investigate the relationship between promoter hypermethylation and PMD hypomethylation, we calculated methylation levels in variably sized windows surrounding CGI promoters (Fig. 4c) . Promoters that were hypermethylated within about 1 kb of the CGI boundary tended to be more hypomethylated starting from about 10 kb to more than a Mb away. This is apparent in a 10-Mb region (Fig. 4d) where focal hypermethylation peaks (red spikes in the methylation change track) are found primarily within hypomethylated PMDs. This relationship held true genome wide even after controlling for expression levels of the associated genes (Supplementary Fig. 9) , with 57% of methylation-prone elements and only 19% of methylation-resistant elements being located within PMDs (Supplementary Fig. 6 ). At gene promoters, associated hypomethylation occurred both upstream and downstream of the TSS (Fig. 4c) , indicating that observations about differential methylation at gene bodies 21, 22 may be at least partially a consequence of these longer, multi-gene PMDs.
Previously, multi-gene domains of long-range epigenetic silencing (LRES) were identified on the basis of gene expression in prostate cancer cells 23, 24 . Some prostate LRESs from these studies 24 clearly coincided with our colon PMDs, and overall the genes within these two sets overlapped significantly (P < 0.0001; Supplementary  Figs. 10,16) . However, our PMDs did not significantly overlap with prostate LRESs at the bp level, which is likely to be a consequence of the lower resolution of the LRES study. We did, however, observe a striking correspondence between tumor PMDs and nuclear-lamina-associated domains (LADs 25 ) in TIG3 fibroblast cells (Fig. 4d) . Because dynamic association and dissociation with the nuclear lamina has been implicated as a key mechanism in the developmental regulation of long-range gene silencing 26 , we investigated a large region containing several PMD boundaries specific to either the colon tumor or IMR-90 fibroblasts (Fig. 5a) . This region contains two tumor suppressor genes subject to frequent epigenetic silencing in epithelial tumors, NRG1 (ref. 27 ) and SFRP1 (ref. 28 ), both of which had hypermethylated promoters and reduced expression in our tumor. Both genes fell within colontumor-specific PMDs, with the SFRP1 promoter defining a PMD boundary present in IMR-90 cells but not the tumor (Fig. 5b) . Determining whether such cell-type-specific boundaries arise during normal lineage specification or oncogenesis will require additional study, but recent work has shown that loss of key boundary l e t t e r s elements such as CTCF sites can cause aberrant spreading of silencing domains in cancer 29 . Profiling tumor PMDs will allow exploration into whether chromosomal rearrangements can also lead to aberrant silencing boundaries.
Intrigued by the SFRP1 boundary promoter, we investigated the genome-wide distribution of various genomic annotations with respect to PMD boundaries ( Fig. 5c and Supplementary  Fig. 11 ). We confirmed that methylation-prone CGI promoters were enriched within PMDs, but we found that they were most abundant within the first 150 kb of the PMDs, a pattern similar to that of the hESC polycomb mark relative to LAD boundaries 25 ( Fig. 5c, upper left) . Conversely, methylation-resistant CGI promoters were depleted within PMDs but were strongly enriched within 10 kb of the boundary itself, as shown at SFRP1 (Fig. 5c, upper right) . Only methylation-resistant promoters facing away from the PMD were enriched at the boundary; those promoters facing into the PMD were depleted, which is suggestive of a mechanistic link between gene transcription and PMD boundary formation. Comparisons to ENCODE ChIP-seq data revealed other factors that were enriched at PMD boundaries, including CTCF and SIN3A, the latter of which was enriched at the PMD boundary but was almost completely absent within the PMD itself (Fig. 5c, lower left) . LAD boundaries from IMR-90 cells strongly coincided with colon tumor PMD boundaries (Fig. 5c, lower right) .
We used IMR-90 data to investigate the relationship between PMD boundaries and histone-modification profiles in the same cells 30 (Fig. 5d, top) . The promoter-associated H3K4me3 mark was enriched at PMD boundaries and was somewhat depleted within PMDs, whereas the combinatorial H3K4me1/3 enhancer signature 31 was almost completely absent within PMDs. The heterochromatinassociated H3K9me3 mark was enriched within deeply internal portions of PMDs. IMR-90 PMD boundaries also coincided with boundaries of late-replication domains in fibroblasts 32 (Fig. 5d, bottom) , a feature that may contribute mechanistically to their DNA methylation loss over repeated cell divisions 33 . In the three-dimensional structure of the nucleus, IMR-90 PMDs corresponded to one of the two major nuclear compartments identified using whole-genome chromatin conformation capture (Hi-C) in lymphoblastoid cells 34 .
We confirmed the spatial association of hypermethylation and hypomethylation within PMDs using DNA methylation array data from an independent and diverse set of 25 colon and rectal tumors and matched adjacent tissue 6 (Fig. 6) . We used stringent tumor to normal l e t t e r s comparisons to characterize array features in one of four categories for each tumor: methylation resistant, methylation prone, partial methylation loss or constitutively methylated ( Fig. 6a and Supplementary  Fig. 12 ). The extent of hypermethylation and hypomethylation were highly correlated within each tumor (Fig. 6b) , suggesting the presence of a single cancer cell population that accumulates both alterations simultaneously. In each tumor, methylation-prone and partialmethylation-loss loci were preferentially localized within the tumor PMDs relative to the invariant methylation-resistant and constitutively methylated loci (Fig. 6c) . Two conclusions can be drawn from these observations: (i) colorectal tumors in general contain hypomethylated PMDs relative to adjacent normal colon, and (ii) focal hypermethylation and long-range hypomethylation are associated within these PMD domains. These two phenomena appear to be linked through a developmentally regulated 26 and evolutionarily conserved 35 mechanism involving the higher-order organization of chromatin within the nucleus and DNA replication timing 32 . How the two are decoupled in immortalized cell lines, which do have clear PMDs but not widespread focal hypermethylation, will give insights into the specific gene-silencing mechanisms used by cancer cells 36 . These findings show the power of bisulfite-seq to detect both local changes (that is, at promoters, enhancers or insulators) and higher-order chromatin structure in a single assay using clinical DNA samples. 
